Department of Radiation Oncology, People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, Xinjiang 830001, China.
Xinjiang Medical University, Urumqi, Xinjiang 830054, China.
Biomed Res Int. 2020 Aug 8;2020:3929435. doi: 10.1155/2020/3929435. eCollection 2020.
Low molecular heparin (LWMH) therapy can prevent the occurrence of VTE in tumor patients and may have a direct antitumor effect. However, the expression pattern of VEGF-A and microRNAs was less reported in cervical cancer subjects who received concurrent chemoradiotherapy (CCRT) or received anticoagulant treatment with low molecular weight heparin (LWMH) after CCRT (CCRT+LWMH).
In this study, 30 cervical cancer subjects treated with CCRT and 30 cervical cancer patients treated with CCRT+LWMH were enrolled. We screened five miRNAs (miR-15a-5p, miR-16-5p, miR-29a-3p, miR-195-5p, and miR-205-5p), which have multiple binding sites with VEGF-A and are highly expressed in serum of patients with cervical cancer, by RT-qPCR. The expression level of VEGF-A was also detected by RT-qPCR and ELISA. Statistical methods were used for difference and correlation analyses.
We observed the curative effect in the two treatment methods. In the CCRT group, the total effective rate was 60.00%, and in the CCRT+LWMT group, the total effective rate was 83.33% ( = 0.013, = 6.129). Additionally, the serum levels of VEGF-A in the CCRT+LWMH group were downregulated, relative to the CCRT group ( < 0.05), and VEGF-A in serum was significantly positively correlated with venous thromboembolism (VTE) ( = 2.134, = 0.035). Only miR-205-5p and miR-195-5p were upregulated in CCRT+LWMH, relative to CCRT ( < 0.05). In serum of patients with cervical cancer after CCRT+LWMH treatment, there was no significant correlation between VEGF-A and miR-15a-5p ( = -0.132, = 0.209), miR-16-5p ( = -0.205, = 0.311), or miR-29a-3p ( = -0.029, = 0.662), but VEGF-A was significantly negatively correlated with miR-195-5p ( = -0.396, = 0.040) and miR-205-5p ( = -0.315, = 0.032). Furthermore, VTE was also significantly negatively correlated with miR-195-5p ( = -0.412, = 0.031) and miR-205-5p ( = -0.123, = 0.044).
These data revealed roles for VEGF-A and these miRNAs as potential biomarkers in cervical cancer patients with VTE, which exhibited usage potential in the treatment of venous thromboembolism.
低分子肝素（LWMH）治疗可预防肿瘤患者发生静脉血栓栓塞症（VTE），并且可能具有直接的抗肿瘤作用。然而，在接受同步放化疗（CCRT）或在 CCRT 后接受低分子量肝素（LWMH）抗凝治疗的宫颈癌患者中，VEGF-A 和 microRNAs 的表达模式报道较少。
本研究纳入了 30 例接受 CCRT 治疗的宫颈癌患者和 30 例接受 CCRT+LWMH 治疗的宫颈癌患者。我们通过 RT-qPCR 筛选了五个与 VEGF-A 有多个结合位点且在宫颈癌患者血清中高表达的 microRNAs（miR-15a-5p、miR-16-5p、miR-29a-3p、miR-195-5p 和 miR-205-5p）。我们还通过 RT-qPCR 和 ELISA 检测了 VEGF-A 的表达水平。我们使用统计学方法进行了差异和相关性分析。
我们观察了两种治疗方法的疗效。在 CCRT 组中，总有效率为 60.00%，而在 CCRT+LWMH 组中，总有效率为 83.33%（ = 0.013， = 6.129）。此外，与 CCRT 组相比，CCRT+LWMH 组的血清 VEGF-A 水平下调（ < 0.05），并且 VEGF-A 与静脉血栓栓塞症（VTE）显著正相关（ = 2.134， = 0.035）。仅 miR-205-5p 和 miR-195-5p 在 CCRT+LWMH 中上调，与 CCRT 相比（ < 0.05）。在接受 CCRT+LWMH 治疗后的宫颈癌患者的血清中，VEGF-A 与 miR-15a-5p（ = -0.132， = 0.209）、miR-16-5p（ = -0.205， = 0.311）或 miR-29a-3p（ = -0.029， = 0.662）之间均无显著相关性，但 VEGF-A 与 miR-195-5p（ = -0.396， = 0.040）和 miR-205-5p（ = -0.315， = 0.032）呈显著负相关。此外，VTE 也与 miR-195-5p（ = -0.412， = 0.031）和 miR-205-5p（ = -0.123， = 0.044）显著负相关。
这些数据揭示了 VEGF-A 和这些 microRNAs 作为宫颈癌患者 VTE 的潜在生物标志物的作用，它们在治疗静脉血栓栓塞症方面具有潜在的应用价值。
